{"id":"energi-f701","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, ENERGI-F701 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.","oneSentence":"ENERGI-F701 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:50:57.268Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT03351322","phase":"PHASE2","title":"ENERGI-F701 for Female Hair Loss Treatment","status":"COMPLETED","sponsor":"Energenesis Biomedical Co., Ltd.","startDate":"2018-05-23","conditions":"Female Pattern Baldness, Hair Loss, Alopecia","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ENERGI-F701","genericName":"ENERGI-F701","companyName":"Energenesis Biomedical Co., Ltd.","companyId":"energenesis-biomedical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ENERGI-F701 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}